ADMINISTRATION DE CHARGE UTILE SPECIFIQUE DE TUMEUR ET ACTIVATION IMMUNITAIRE AU MOYEN D'UN ANTICORPS HUMAIN CIBLANT UN ANTIGENE DE SURFACE DE CELLULE TUMORALE TRES SPECIFIQUE
This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.